XBIO — what changed in the latest 10-Q
A section-by-section comparison of XBIO's newest periodic SEC filing (10-K/10-Q) against the prior same-form filing: paragraphs added and removed per section, with verbatim excerpts. Purely a deterministic text diff — no similarity scores, no directional read, not investment advice.
Comparing 10-Q · 2026-08-06 vs the prior 10-Q · 2026-05-12
| Section | Outcome | Added | Removed | Minor | Unchanged |
|---|---|---|---|---|---|
| MD&A | Text added/removed | +66 | −5 | ~19 | 48 |
| Market risk (Item 3) | Text added/removed | +115 | 0 | ~5 | 12 |
| Controls & procedures | Text added/removed | +116 | 0 | ~5 | 11 |
| Legal proceedings | Text added/removed | +119 | 0 | ~4 | 9 |
| Risk factors | No material changes reported (points to the 10-K) | — | — | — | — |
| Other information | Text added/removed | +122 | −1 | ~3 | 6 |
Counts are paragraphs; added/removed means text added or removed vs the prior filing — no direction or judgement implied.
Representative excerpts
Up to 5 excerpts of about 300 characters per section, quoted verbatim from the two SEC filings.
MD&A
Text added vs the prior filing · source: 10-Q · 2026-08-06
Item 3 Quantitative and Qualitative Disclosures About Market Risk 22
Item 2 Unregistered Sales of Equity Securities and Use of Proceeds 23
Accrued expenses and other current liabilities 572,440 709,916
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
Text removed vs the prior filing · source: 10-Q · 2026-05-12
In some cases, these statements may be identified by terminology such as “may,” “will,” “would,” “could,” “should,” “expect,” “plan,”
“anticipate,” “believe,” “estimate,” “seek,” “approximately,” “intend,” “predict,” “potential,” “projects,” “upcoming”, “opportunity”, “target” or “continue,” or the negative of such terms and other comparable terminology. Although we believe that the expectations reflected in the forward-looking st…
We incurred a net loss of approximately $456,000 for the three months ended March 31, 2026. We had an accumulated deficit of approximately $200.3 million at March 31, 2026, as compared to an accumulated deficit of approximately $199.9 million at December 31, 2025. Working capital was approximately $…
Our principal source of liquidity consists of cash. At March 31, 2026, we had approximately $7.3 million in cash and $1.0 million in current liabilities. At December 31, 2025, we had approximately $7.9 million in cash and $1.0 million in current liabilities. We have historically relied upon sales of…
Cash flows used in operating activities for the three months ended March 31, 2026 totaled approximately $0.5 million, which was primarily due to our net loss for the period and, to a lesser extent, a decrease in accounts payable, accrued expenses and other liabilities. Cash flows used in operating a…
Market risk (Item 3)
Text added vs the prior filing · source: 10-Q · 2026-08-06
Item 2 Unregistered Sales of Equity Securities and Use of Proceeds 23
Accrued expenses and other current liabilities 572,440 709,916
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
Issuance of common stock in connection with restricted stock – – 7,000 7 (7) – – – –
Controls & procedures
Text added vs the prior filing · source: 10-Q · 2026-08-06
Item 2 Unregistered Sales of Equity Securities and Use of Proceeds 23
Accrued expenses and other current liabilities 572,440 709,916
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
Issuance of common stock in connection with restricted stock – – 7,000 7 (7) – – – –
Legal proceedings
Text added vs the prior filing · source: 10-Q · 2026-08-06
Item 2 Unregistered Sales of Equity Securities and Use of Proceeds 23
Accrued expenses and other current liabilities 572,440 709,916
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
Issuance of common stock in connection with restricted stock – – 7,000 7 (7) – – – –
Other information
Text added vs the prior filing · source: 10-Q · 2026-08-06
Accrued expenses and other current liabilities 572,440 709,916
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
Issuance of common stock in connection with restricted stock – – 7,000 7 (7) – – – –
Issuance of common stock in connection with restricted stock – – 7,000 7 (7) – – – –
Text removed vs the prior filing · source: 10-Q · 2026-05-12
During the quarter ended March 31, 2026, no director or officer adopted or terminated any Rule 10b5-1 trading arrangement or non-Rule 10b5-1 trading arrangement, as each term is defined in Item 408(a) of Regulation S-K.
How to read Risk Factors (Item 1A) in a 10-Q
A 10-Q risk-factor section usually takes one of three forms; this page classifies it as one of:
- Pointer — the filer states there have been no material changes and points back to the annual 10-K risk factors; there is no own risk text to compare this quarter.
- Partial update — the filer carves out specific updated risks ("except as set forth below"); the excerpts show exactly what is new this quarter.
- Restated in full — the quarter carries the complete risk-factor text. When the prior quarter was only a pointer there is no prior full text to diff against, so the page flags the section as restated instead.
This describes the filing structure only — it is never a judgement on whether risk went up or down.
Source: text-level diff of the two SEC EDGAR filings · deterministic (no AI-generated content) · for reference only · not investment advice